### AMGEN INC.

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock



#### **Company Profile**

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	30,332,000,000		22,186,000,000		19,385,000,000	
Common stock capital		33,070,000,000		32,514,000,000		32,096,000,000
Fixed assets	66,822,000,000		42,935,000,000		41,780,000,000	
Equity capital of a company		6,232,000,000		3,661,000,000		6,700,000,000
Cash and cash equivalents	10,944,000,000		7,629,000,000		7,989,000,000	
Accrued liabilities		4,680,000,000		5,757,000,000		6,594,000,000
Other assets	-		-		-	
Current liabilities		18,392,000,000		15,687,000,000		12,184,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		72,530,000,000		45,773,000,000		42,281,000,000
Different income		-		-		-
Other liabilities		1,635,000,000		2,123,000,000		1,940,000,000
Total assets	97,154,000,000	97,154,000,000	65,121,000,000	65,121,000,000	61,165,000,000	61,165,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	26,700	25,200	24,200
Equity ratio	6.41%	5.62%	10.95%
Debt-equity ratio	1,458.95%	1,678.78%	812.91%

#### **Others**

	2023	2022	2021
Tax Expense Rate	14.49%	10.81%	12.06%

# **AMGEN INC.**

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	28,010,000,000	26,092,000,000	25,987,000,000
Net income	6,717,000,000	6,552,000,000	5,893,000,000
EBIT	10,043,584,500	8,200,512,000	7,415,929,500
Operating income before taxes	7,855,000,000	7,346,000,000	6,701,000,000
Cash Flow	8,471,000,000	9,721,000,000	9,261,000,000
Net interest income	-2,962,000,000	-1,486,000,000	-1,286,000,000
Research and development expenses	4,755,000,000	4,434,000,000	4,819,000,000
Income taxes	1,138,000,000	794,000,000	808,000,000
Result from investments in subsidaries, associates and other	-	-	0
Revenues per employee	974,056	961,366	997,063

## **Board of Directors**

Members of Management Board		
Brian Druker	Member of Board of Directors	
Michael Drake	Member of Board of Directors	
Omar Ishrak	Member of Board of Directors	
Robert Williams	Member of Board of Directors	
Ronald Sugar	Member of Board of Directors	
Tyler Jacks	Member of Board of Directors	
Wanda Austin	Member of Board of Directors	
Amy Miles	Member of Board of Directors	
Charles Holley	Member of Board of Directors	
Ellen Kullman	Member of Board of Directors	
Greg Garland	Member of Board of Directors	
Robert Eckert	Member of Board of Directors	
Robert A. Bradway	Chairman of Managing Board	
David M. Reese	Member of Executive Committee	
Jackie Elbonne	Member of Executive Committee	
James Bradner	Member of Executive Committee	
Jonathan Graham	Member of Executive Committee	
Mike Zahigan	Member of Executive Committee	
Murdo Gordon	Member of Executive Committee	
Paul Burton	Member of Executive Committee	
Peter Griffith	Member of Executive Committee	